Loading...
(177)Lu-DOTATATE Peptide Receptor Radionuclide Therapy in Metastatic or Advanced and Inoperable Primary Neuroendocrine Tumors of Rare Sites
The present study aimed at exploring the patient and imaging characteristics of primary neuroendocrine tumors (NETs) of rare sites who presented with metastatic and/or advanced inoperable stages and therefore was considered for peptide receptor radionuclide therapy (PRRT) with (177)Lu-DOTATATE. A re...
Na minha lista:
| Udgivet i: | World J Nucl Med |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Medknow Publications & Media Pvt Ltd
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5460307/ https://ncbi.nlm.nih.gov/pubmed/28670182 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/1450-1147.207283 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|